Tuberculosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Tuberculosis Pipeline Drugs Market Overview

The symptoms of tuberculosis range from no symptoms (latent tuberculosis) to symptoms of active disease. Symptoms include an overall sensation of feeling unwell, cough, possibly bloody mucus, fatigue, shortness of breath, weight loss, and pain in the chest.

The Tuberculosis pipeline market research report provides comprehensive information on the therapeutics under development for Tuberculosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Tuberculosis and features dormant and discontinued projects.

Tuberculosis Pipeline Products Market Segmentation by Targets

The key targets in the Tuberculosis pipeline products market are FAD-Dependent Decaprenylphosphoryl-Beta-D-Ribofuranose 2-Oxidase, Mycobacterium tuberculosis Protein Ag85A, 23S Ribosomal RNA, H+ Transporting Two Sector ATPase, Enoyl [Acyl Carrier Protein] Reductase [NADH] FabI, Mycobacterium tuberculosis ESAT 6 Protein EsxA, RNA Polymerase, Transmembrane Transport Protein mmpL3, 16S Ribosomal RNA, Enoyl [Acyl Carrier Protein] Reductase [NADH], and others.

Tuberculosis Pipeline Products Market Analysis by Targets

Tuberculosis Pipeline Products Market Analysis by Targets

For more target insights into the Tuberculosis pipeline products market, download a free report sample

Tuberculosis Pipeline Products Market Segmentation by Mechanisms of Action

The key mechanisms of action in the Tuberculosis pipeline products market are FAD-Dependent Decaprenylphosphoryl-Beta-D-Ribofuranose 2-Oxidase Inhibitor, 23S Ribosomal RNA Inhibitor, H+ Transporting Two Sector ATPase Inhibitor, Enoyl [Acyl Carrier Protein] Reductase [NADH] FabI Inhibitor, RNA Polymerase Inhibitor, Transmembrane Transport Protein mmpL3 Inhibitor, 16S Ribosomal RNA Inhibitor, Enoyl [Acyl Carrier Protein] Reductase [NADH] Inhibitor, Cell Wall Synthesis Inhibitor, DNA Synthesis Inhibitor, and others.

Tuberculosis Pipeline Products Market Analysis by Mechanisms of Action

Tuberculosis Pipeline Products Market Analysis by Mechanisms of Action

For more mechanisms of action insights into the Tuberculosis pipeline products market, download a free report sample

Tuberculosis Pipeline Products Market Segmentation by Routes of Administration

The key routes of administration in the Tuberculosis pipeline products market are oral, inhalational, intramuscular, intradermal, intravenous, parenteral, nasal, subcutaneous, intravesical, sublingual, and topical.

Tuberculosis Pipeline Products Market Analysis by Routes of Administration

Tuberculosis Pipeline Products Market Analysis by Routes of Administration

For more routes of administration insights into the Tuberculosis pipeline products market, download a free report sample

Tuberculosis Pipeline Products Market Segmentation by Molecule Types

The key molecule types in the Tuberculosis pipeline products market are small molecule, subunit vaccine, recombinant vector vaccine, vaccine, live attenuated vaccine, inactivated vaccine, cell therapy, DNA vaccine, monoclonal antibody conjugated, mRNA vaccine, and others.

Tuberculosis Pipeline Products Market Analysis by Molecule Types

Tuberculosis Pipeline Products Market Analysis by Molecule Types

For more molecule type insights into the Tuberculosis pipeline products market, download a free report sample

Competitive Landscape

Some of the leading players in the Tuberculosis pipeline products market are GSK plc, Quratis Inc, Vichem Chemie Research Ltd, Chongqing Zhifei Biological Products Co Ltd, Collaborations Pharmaceuticals Inc, Sequella Inc, Bioversys AG, Chengdu Keen Biotechnology Co Ltd, Eli Lilly and Co, and Microbiotix Inc.

Tuberculosis Pipeline Products Market Analysis by Players

Tuberculosis Pipeline Products Market Analysis by Players

To know more about the leading players in the Tuberculosis pipeline products market, download a free report sample

Tuberculosis Pipeline Products Market Report Overview

Key Targets FAD-Dependent Decaprenylphosphoryl-Beta-D-Ribofuranose 2-Oxidase, Mycobacterium tuberculosis Protein Ag85A, 23S Ribosomal RNA, H+ Transporting Two Sector ATPase, Enoyl [Acyl Carrier Protein] Reductase [NADH] FabI, Mycobacterium tuberculosis ESAT 6 Protein EsxA, RNA Polymerase, Transmembrane Transport Protein mmpL3, 16S Ribosomal RNA, Enoyl [Acyl Carrier Protein] Reductase [NADH], and Others
Key Mechanisms of Action FAD-Dependent Decaprenylphosphoryl-Beta-D-Ribofuranose 2-Oxidase Inhibitor, 23S Ribosomal RNA Inhibitor, H+ Transporting Two Sector ATPase Inhibitor, Enoyl [Acyl Carrier Protein] Reductase [NADH] FabI Inhibitor, RNA Polymerase Inhibitor, Transmembrane Transport Protein mmpL3 Inhibitor, 16S Ribosomal RNA Inhibitor, Enoyl [Acyl Carrier Protein] Reductase [NADH] Inhibitor, Cell Wall Synthesis Inhibitor, DNA Synthesis Inhibitor, and Others
Key Routes of Administration Oral, Inhalational, Intramuscular, Intradermal, Intravenous, Parenteral, Nasal, Subcutaneous, Intravesical, Sublingual, and Topical
Key Molecule Type Small Molecule, Subunit Vaccine, Recombinant Vector Vaccine, Vaccine, Live Attenuated Vaccine, Inactivated Vaccine, Cell Therapy, DNA Vaccine, Monoclonal Antibody Conjugated, mRNA Vaccine, and Others
Leading Players GSK plc, Quratis Inc, Vichem Chemie Research Ltd, Chongqing Zhifei Biological Products Co Ltd, Collaborations Pharmaceuticals Inc, Sequella Inc, Bioversys AG, Chengdu Keen Biotechnology Co Ltd, Eli Lilly and Co, and Microbiotix Inc

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Tuberculosis (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Tuberculosis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Tuberculosis (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Tuberculosis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews the latest news related to pipeline therapeutics for Tuberculosis (Infectious Disease)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Tuberculosis (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Tuberculosis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.

AdjuTec Pharma AS
Archivel Farma SL
Astellas Pharma Inc
AstraZeneca Plc
Astria Therapeutics Inc
Atomwise Inc
Austrianni GmbH
BioLingus AG
BioNTech SE
Bioversys AG
Bristol-Myers Squibb Co
C&O Pharmaceutical Technology (Holdings) Ltd
CanSino Biologics Inc
Changzhou Yinsheng Pharmaceutical Co Ltd
Chengdu Keen Biotechnology Co Ltd
Chongqing Zhifei Biological Products Co Ltd
Collaborations Pharmaceuticals Inc
Consegna Pharma Inc
Crestone Inc
Daiichi Sankyo Co Ltd
Demuris Ltd
Eisai Co Ltd
Eli Lilly and Co
Ena Therapeutics Pty Ltd
Enyo Pharma SA
EpiVax Inc
Evotec SE
Exscientia Plc
Eyam Vaccines and Immunotherapeutics Ltd
EyeGene Inc
Fimbrion Therapeutics Inc
Gamaleya Federal Research Center of Epidemiology and Microbiology
GC Biopharma Corp
Genu Pharma Co Ltd
Globeimmune Inc
Greffex Inc
GSK plc
Guangdong Zhongsheng Pharmaceutical Co Ltd
Guangzhou Egg Biotechnology Co Ltd
HanaVax Inc
Hsiri Therapeutics LLC
ILiAD Biotechnologies LLC
Immodulon Therapeutics Ltd
Immunitor Inc
ImmunoBiology Ltd
Innovare R & D SA De CV
Jiangsu Recbio Technology Co Ltd
L2 Diagnostics LLC
Lead Discovery Center GmbH
LegoChem Biosciences Inc
MannKind Corp
Medicines Development for Global Health Ltd
Merck & Co Inc
MetalloPharm LLC
Microbiotix Inc
Mountain Valley MD Holdings Inc
Mycosynthetix Inc
Nearmedic Plus
Neuro Horizon Pharma LLC
NovoBiotic Pharmaceuticals LLC
NTxBio LLC
Nykode Therapeutics ASA
Opal Biosciences Ltd
Otsuka Pharmaceutical Co Ltd
Pai Life Sciences Inc
Palisades Therapeutics
Pathens Inc
PDS Biotechnology Corp
PeptiDream Inc
Pfizer Inc
Pharmapraxis
Pharmasyntez
Primetime Life Sciences LLC
Protibea Therapeutics Inc
Quratis Inc
QureTech Bio AB
Qurient Co Ltd
Sanofi
Sentan Pharma Inc
Sequella Inc
Serum Institute of India Pvt Ltd
Shanghai H&G Biotech
Shanghai Jiatan Pharmaceutical Technology Co Ltd
Spero Therapeutics Inc
Sphaera Pharma Pte Ltd
Standigm Inc
Target Medicals
Tibet Rhodiola Pharmaceutical Holding Co Ltd
TVAX Biomedical Inc
Tydock Pharma Srl
Uvax Bio LLC
Vaxil Bio Therapeutics Ltd
Vaxinano SE
Vaxine Pty Ltd
Vaxxit Srl
Vichem Chemie Research Ltd
Vir Biotechnology Inc
Zata Pharmaceuticals Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Tuberculosis – Overview

Tuberculosis – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Tuberculosis – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Tuberculosis – Companies Involved in Therapeutics Development

Tuberculosis – Drug Profiles

Tuberculosis – Dormant Projects

Tuberculosis – Discontinued Products

Tuberculosis – Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Tuberculosis, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Target, 2022 (Contd..1)

Number of Products by Stage and Target, 2022 (Contd..2)

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)

Number of Products by Stage and Mechanism of Action, 2022 (Contd..2)

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Tuberculosis – Dormant Projects, 2022

Tuberculosis – Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development for Tuberculosis, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

Frequently asked questions

  • What are the key targets in the Tuberculosis pipeline products market?

    The key targets in the Tuberculosis pipeline products market are FAD-Dependent Decaprenylphosphoryl-Beta-D-Ribofuranose 2-Oxidase, Mycobacterium tuberculosis Protein Ag85A, 23S Ribosomal RNA, H+ Transporting Two Sector ATPase, Enoyl [Acyl Carrier Protein] Reductase [NADH] FabI, Mycobacterium tuberculosis ESAT 6 Protein EsxA, RNA Polymerase, Transmembrane Transport Protein mmpL3, 16S Ribosomal RNA, Enoyl [Acyl Carrier Protein] Reductase [NADH], and others.

  • What are the key mechanisms of action in the Tuberculosis pipeline products market?

    The key mechanisms of action in the Tuberculosis pipeline products market are FAD-Dependent Decaprenylphosphoryl-Beta-D-Ribofuranose 2-Oxidase Inhibitor, 23S Ribosomal RNA Inhibitor, H+ Transporting Two Sector ATPase Inhibitor, Enoyl [Acyl Carrier Protein] Reductase [NADH] FabI Inhibitor, RNA Polymerase Inhibitor, Transmembrane Transport Protein mmpL3 Inhibitor, 16S Ribosomal RNA Inhibitor, Enoyl [Acyl Carrier Protein] Reductase [NADH] Inhibitor, Cell Wall Synthesis Inhibitor, DNA Synthesis Inhibitor, and others.

  • What are the key routes of administration in the Tuberculosis pipeline products market?

    The key routes of administration in the Tuberculosis pipeline products market are oral, inhalational, intramuscular, intradermal, intravenous, parenteral, nasal, subcutaneous, intravesical, sublingual, and topical.

  • What are the key molecule types in the Tuberculosis pipeline products market?

    The key molecule types in the Tuberculosis pipeline products market are small molecule, subunit vaccine, recombinant vector vaccine, vaccine, live attenuated vaccine, inactivated vaccine, cell therapy, DNA vaccine, monoclonal antibody conjugated, mRNA vaccine, and others.

  • Who are the leading players in the Tuberculosis pipeline products market?

    Some of the leading players in the Tuberculosis pipeline products market are GSK plc, Quratis Inc, Vichem Chemie Research Ltd, Chongqing Zhifei Biological Products Co Ltd, Collaborations Pharmaceuticals Inc, Sequella Inc, Bioversys AG, Chengdu Keen Biotechnology Co Ltd, Eli Lilly and Co, and Microbiotix Inc.

Tuberculosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$2,500

Can be used by individual purchaser only

$7,500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Tuberculosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Tuberculosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Tuberculosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.